Pfizer to Merge Its Off-Patent Drug Unit With Mylan

Pfizer agreed on Monday to combine its off-patent drugs division, which sells treatments like the cholesterol drug Lipitor, with the pharmaceutical company Mylan, creating a potential powerhouse in the increasingly challenging business of producing generic medicines.

https://www.nytimes.com/2019/07/29/business/dealbook/pfizer-mylan-deal.html